All News

These patients had a higher spleen-to-liver stiffness ratio than those with alcohol-related liver disease, warranting a closer look at testing.

Funding cuts to childhood cancer research have put the subspecialty in a precarious position during Childhood Cancer Awareness Month.

The ease of acquiring prior authorizations for a new formulary drug plays a part in evaluating oncology drugs that are new to the market.

The Trump administration highlighted a potential autism risk from prenatal acetaminophen use, but studies demonstrate conflicting evidence.

Only a fraction of countries in the world have designated chronic kidney disease as a health priority.

Patients with progressive pulmonary fibrosis had longer survival with antifibrotic therapy, but only if they met a key criteria.

As oncology continues to move more toward precision medicine, tools like EVOFLUx may offer a more personalized roadmap from diagnosis to treatment.

Medicare beneficiaries with near low income struggle most with health care affordability, highlighting gaps in financial assistance programs.

Cemiplimab demonstrated a 56% overall survival rate, making it a potential option for physicians to use for treating non–small cell lung cancer (NSCLC).

Same-sex couples now report higher insurance coverage than different-sex couples, but disparities by income, geography, and marital status remain.

New research highlights caregiver perspectives to improve colorectal cancer screening access for individuals with intellectual and developmental disabilities.

Tirzepatide appears more cost-effective than semaglutide for obesity and knee osteoarthritis, though long-term data and patient-centered outcomes remain key.

Refat Rasul Srejon, MPH, recommends employer coverage for substance use care and follow-up, plus research on local treatment and drug trends.

National survey data show rural residents are less likely to receive colorectal cancer screening, with socioeconomic and structural barriers driving the gap.

Patients with acute myeloid leukemia (AML) in remission for over 3 years experience survival rates comparable with a matched cohort from the general population.

The American Heart Association (AHA) launched a news initiative to address challenges with in-hospital care for patients with different types of heart failure.

Female patients with chronic spontaneous urticaria (CSU) face greater disease severity and burdens, particularly in midlife, a study found.

Positive topline data from the phase 3 BRUIN CLL-313 showed pirtobrutinib's efficacy in the frontline setting.

This case highlights the diagnostic complexity and clinical management challenges of dual hematologic malignancies.

Findings from the ROCKET-SHUTTLE trial reveal the benefits of combining the anti-OX40 monoclonal antibody with topical therapies for atopic dermatitis.

The approval allows all patients 12 years and older to use pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection for solid tumor indications approved for intravenous pembrolizumab.

Research shows more than a third of patients with rheumatoid arthritis met criteria for frailty, with prefrailty and robust groups closely following.

Patients with acute exacerbations of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis face steep odds and benefit from palliative care.

A randomized trial shows low-dose aspirin halved recurrence rates in patients with PI3K pathway gene alterations.

Research reveals that patients with both rheumatoid arthritis and MASH cirrhosis face significantly higher cardiovascular risks.

The Oncotype DX 21-gene recurrence score helps guide adjuvant therapy in women with early-stage breast cancer and low genomic risk.

Ruxolitinib cream received an expanded approval to treat patients as young as 2 years old with non-immunocompromised mild to severe atopic dermatitis.

Tirzepatide’s cost-effectiveness provides key evidence for policy makers implementing clinical coverage decisions.

With vaccination rates slipping and new policies emerging, parents need to know what’s changing as kids head back to the classroom.

Efgartigimod shows promising early response in generalized myasthenia gravis, especially in patients with short disease duration and severe bulbar symptoms.